查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1580918

FASN 抑制劑市場：按藥物類型、給藥途徑、應用和最終用戶分類 - 全球預測 2025-2030

FASN Inhibitor Market by Drug Type (Natural Product Inhibitors, Peptide Inhibitors, Small Molecule Inhibitors), Route of Administration (Intravenous, Oral), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年FASN抑制劑市值為3.2935億美元，預計到2024年將達到3.5656億美元，複合年成長率為8.32%，到2030年將達到5.7638億美元。

FASN（脂肪酸合成酶）抑制劑代表一組針對負責合成棕櫚酸的酵素的治療藥物，棕櫚酸是一種對脂質生物合成和能量代謝很重要的飽和脂肪酸。這些抑制劑主要在腫瘤學應用中感興趣。這是因為癌細胞的脂肪生成增強，並依賴 FASN 進行增殖和存活。癌症盛行率的增加和研發投資的增加凸顯了對 FASN 抑制劑等創新治療方法的需求，特別是擴大在代謝疾病和肥胖症方面的應用。最終用途範圍延伸至製藥公司、研究機構和潛在的食品產業的代謝健康解決方案。關鍵的成長要素包括癌症發病率上升、生物技術的進步以及加速藥物開發的產學合作。一些商機正在出現，包括利用人工智慧和機器學習進行藥物發現、探索聯合治療以提高療效，以及擴展到擁有發達醫療基礎設施的區域市場。然而，市場面臨挑戰，包括高昂的開發成本、嚴格的監管障礙以及可能阻礙採用的潛在副作用。智慧財產權問題和證明人體功效的臨床試驗數量有限也是主要障礙。創新領域包括識別用於患者分層的新型生物標記、改進遞送方法以提高生物有效性以及開發下一代高度特異性抑制劑。對競爭格局和策略夥伴關係關係的持續洞察可以推動進步和市場滲透。了解患者需求和監管合規性對於駕馭這一競爭激烈但前景光明的格局至關重要。透過利用新興技術和合作來應對這些挑戰，相關人員將有效利用 FASN 抑制劑市場的動態特性，為癌症和代謝性疾病治療的突破鋪平道路。

主要市場統計
基準年[2023] 3.2935億美元
預測年份 [2024] 35656萬美元
預測年份 [2030] 57638萬美元
複合年成長率（%） 8.32%

市場動態：揭示快速發展的 FASN 抑制劑市場的關鍵市場洞察

FASN 抑制劑市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 代謝性疾病和腫瘤疾病盛行率上升
    • 藥品快速核准監理支援政策
    • FASN抑制劑在治療感染疾病的新用途
  • 市場限制因素
    • 由於需要先進技術和專業原料，FASN抑制劑成本較高
  • 市場機會
    • 策略聯盟和聯合研究以加強研發流程
    • 基於FASN抑制劑的新藥和治療方法的開發
  • 市場挑戰
    • FASN 抑制劑的商業化和開發有限

波特五力：駕馭 FASN 抑制劑市場的策略工具

波特的五力框架是了解 FASN 抑制劑市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 FASN 抑制劑市場的外部影響

外部宏觀環境因素在塑造 FASN 抑制劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解 FASN 抑制劑市場的競爭格局

對 FASN 抑制劑市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 FASN 抑制劑市場供應商的績效評估

FPNV定位矩陣是評估FASN抑制劑市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了 FASN 抑制劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對 FASN 抑制劑市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 代謝性疾病和腫瘤疾病的盛行率上升
      • 支持藥品快速核准的監理政策
      • FASN抑制劑在感染疾病治療的新用途
    • 抑制因素
      • FASN抑制劑很昂貴，因為它們需要先進的技術和特殊的原料。
    • 機會
      • 策略夥伴關係和協作，以增強您的研發流程
      • 基於FASN抑制劑的新藥和治療方法的開發
    • 任務
      • FASN抑制劑的商業化和開發有限
  • 市場區隔分析
    • 藥物類型：勝胜肽抑制劑由於其對標靶的高度特異性而越來越受到青睞。
    • 應用：全球癌症發生率不斷上升，對有效 FASN 抑制劑的需求不斷成長
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 FASN抑制劑依市場藥物類型分類

  • 天然產物抑制劑
  • 勝胜肽抑制劑
  • 小分子抑制劑

第7章 FASN 抑制劑市場：依管理途徑

  • 靜脈
  • 口服

第8章 FASN 抑制劑市場：依應用分類

  • 癌症治療
  • 感染疾病
  • 代謝紊亂

第 9 章 FASN 抑制劑市場：依最終使用者分類

  • 學術研究所
  • 製藥公司

第10章 美洲FASN抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太FASN抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲FASN抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Saguimet Biosciences 宣布 FASN 抑制劑和Semaglutide聯合治療 NASH 的有前景的研究結果
    • Askretis Pharma 完成 ASC40 治療復發性神經膠母細胞瘤關鍵 3 期研究的入組
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Abcam Limited
  • Antipodean Pharmaceuticals
  • Ascletis Pharma Inc.
  • Bio-Techne Corporation
  • Boehringer Ingelheim International GmbH
  • Cayman Chemical Company
  • Enzo Biochem, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Manus Aktteva Biopharma LLP
  • MedChemExpress
  • Merck KGaA
  • Niksan Pharmaceutical
  • Pfizer Inc.
  • Sagimet Biosciences
  • Santa Cruz Biotechnology, Inc.
  • Spansules Pharma
  • Takeda Pharmaceutical Company Limited
  • VWR International by Avantor
Product Code: MRR-6A132FD32B24

The FASN Inhibitor Market was valued at USD 329.35 million in 2023, expected to reach USD 356.56 million in 2024, and is projected to grow at a CAGR of 8.32%, to USD 576.38 million by 2030.

FASN (Fatty Acid Synthase) inhibitors represent a class of therapeutic agents targeting the enzyme responsible for the synthesis of palmitate, a saturated fatty acid crucial for lipid biosynthesis and energy metabolism. These inhibitors are gaining attention primarily in oncological applications, as cancer cells exhibit heightened lipogenesis, relying on FASN for growth and survival. The growing prevalence of cancer, alongside increasing R&D investments, underscores the necessity for innovative treatments like FASN inhibitors, especially with expanding applications in metabolic diseases and obesity. End-use scope extends across pharmaceutical companies, research institutes, and potentially within the nutraceuticals sector for metabolic health solutions. Key growth factors include the rising incidence of cancer, advancements in biotechnology, and collaboration between academia and industry fostering drug development. Several opportunities are emerging, such as leveraging AI and machine learning for drug discovery, exploring combination therapies to enhance efficacy, and expanding into regional markets with supportive healthcare infrastructure. Nevertheless, the market faces challenges, including high developmental costs, stringent regulatory hurdles, and potential adverse effects that hinder widespread adoption. Intellectual property issues and the limited number of trials demonstrating efficacy in humans also pose significant barriers. Innovation areas involve identifying novel biomarkers for patient stratification, improving delivery methods to enhance bioavailability, and developing next-generation inhibitors with greater specificity. Continuous insight into the competitive landscape and strategic partnerships can propel advancements and market penetration. Understanding patient needs and regulatory compliance will be crucial for navigating this competitive yet promising landscape. By addressing these challenges while harnessing emerging technologies and collaborative frameworks, stakeholders can effectively capitalize on the dynamic nature of the FASN inhibitor market, paving the way for breakthroughs in cancer and metabolic disorders treatment.

KEY MARKET STATISTICS
Base Year [2023] USD 329.35 million
Estimated Year [2024] USD 356.56 million
Forecast Year [2030] USD 576.38 million
CAGR (%) 8.32%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving FASN Inhibitor Market

The FASN Inhibitor Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of metabolic and oncological disorders
    • Supportive regulatory policies for expedited drug approval
    • Emerging usage of FASN inhibitors to treat infectious diseases
  • Market Restraints
    • High costs of FASN inhibitors due to need for advanced technology and specialized raw materials
  • Market Opportunities
    • Strategic partnerships and collaborations to enhance research and development processes
    • Development of novel drugs and therapies based on FASN inhibitor
  • Market Challenges
    • Limited commercialization and developments in FASN inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the FASN Inhibitor Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the FASN Inhibitor Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the FASN Inhibitor Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the FASN Inhibitor Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the FASN Inhibitor Market

A detailed market share analysis in the FASN Inhibitor Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the FASN Inhibitor Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the FASN Inhibitor Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the FASN Inhibitor Market

A strategic analysis of the FASN Inhibitor Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the FASN Inhibitor Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam Limited, Antipodean Pharmaceuticals, Ascletis Pharma Inc., Bio-Techne Corporation, Boehringer Ingelheim International GmbH, Cayman Chemical Company, Enzo Biochem, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Manus Aktteva Biopharma LLP, MedChemExpress, Merck KGaA, Niksan Pharmaceutical, Pfizer Inc., Sagimet Biosciences, Santa Cruz Biotechnology, Inc., Spansules Pharma, Takeda Pharmaceutical Company Limited, and VWR International by Avantor.

Market Segmentation & Coverage

This research report categorizes the FASN Inhibitor Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Natural Product Inhibitors, Peptide Inhibitors, and Small Molecule Inhibitors.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Application, market is studied across Cancer Treatment, Infectious Diseases, and Metabolic Disorders.
  • Based on End-User, market is studied across Academic & Research Institutes and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of metabolic and oncological disorders
      • 5.1.1.2. Supportive regulatory policies for expedited drug approval
      • 5.1.1.3. Emerging usage of FASN inhibitors to treat infectious diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of FASN inhibitors due to need for advanced technology and specialized raw materials
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic partnerships and collaborations to enhance research and development processes
      • 5.1.3.2. Development of novel drugs and therapies based on FASN inhibitor
    • 5.1.4. Challenges
      • 5.1.4.1. Limited commercialization and developments in FASN inhibitors
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing preferences for peptide inhibitors due to its highly specificity to their targets
    • 5.2.2. Application: Growing prevalence of cancer across the globe boost the need for effective FASN inhibitor
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. FASN Inhibitor Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Natural Product Inhibitors
  • 6.3. Peptide Inhibitors
  • 6.4. Small Molecule Inhibitors

7. FASN Inhibitor Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral

8. FASN Inhibitor Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Treatment
  • 8.3. Infectious Diseases
  • 8.4. Metabolic Disorders

9. FASN Inhibitor Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Pharmaceutical Companies

10. Americas FASN Inhibitor Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific FASN Inhibitor Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa FASN Inhibitor Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sagimet Biosciences Unveils Promising Study Results on FASN Inhibitor and Semaglutide Combination for NASH Treatment
    • 13.3.2. Ascletis Pharma Completes Enrollment for Crucial Phase III Trial of ASC40 in Recurrent Glioblastoma Treatment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abcam Limited
  • 3. Antipodean Pharmaceuticals
  • 4. Ascletis Pharma Inc.
  • 5. Bio-Techne Corporation
  • 6. Boehringer Ingelheim International GmbH
  • 7. Cayman Chemical Company
  • 8. Enzo Biochem, Inc.
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Johnson & Johnson Services, Inc.
  • 12. Manus Aktteva Biopharma LLP
  • 13. MedChemExpress
  • 14. Merck KGaA
  • 15. Niksan Pharmaceutical
  • 16. Pfizer Inc.
  • 17. Sagimet Biosciences
  • 18. Santa Cruz Biotechnology, Inc.
  • 19. Spansules Pharma
  • 20. Takeda Pharmaceutical Company Limited
  • 21. VWR International by Avantor

LIST OF FIGURES

  • FIGURE 1. FASN INHIBITOR MARKET RESEARCH PROCESS
  • FIGURE 2. FASN INHIBITOR MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FASN INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FASN INHIBITOR MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FASN INHIBITOR MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FASN INHIBITOR MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES FASN INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES FASN INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. FASN INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. FASN INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FASN INHIBITOR MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FASN INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FASN INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FASN INHIBITOR MARKET DYNAMICS
  • TABLE 7. GLOBAL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FASN INHIBITOR MARKET SIZE, BY NATURAL PRODUCT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FASN INHIBITOR MARKET SIZE, BY PEPTIDE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FASN INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FASN INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FASN INHIBITOR MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FASN INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FASN INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FASN INHIBITOR MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FASN INHIBITOR MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES FASN INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. FASN INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. FASN INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023